...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Great Presetation today

As far as the go forward is concerned, yes we are saying the same thing. Yes someone could invest in a 100% owned subsidiary, the only thing that changes is the subsidiary is no longer 100% owned.  That being said dilution then only occurs at the subsidiary level.  Don had said that this was one of the main reasons for the reorg, to prevent dilution of the Royalty Preferreds. Thus far that has not occurred and if this latest investment is in ZCC, as per slide 3, then the dilution in the RPs  continues. Management really seems to have a very hard time with delivering on the simple concept of “say what you mean and mean what you say”. 

Share
New Message
Please login to post a reply